The National Institutes of Health (NIH) is offering a limited competition grant opportunity to support the continuation of the National Clinical Trials Network (NCTN) Biospecimen Banks and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank). This funding aims to maintain and enhance the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens from NCI-funded clinical trials, which are crucial for advancing cancer research and treatment. The estimated total program funding is $19.1 million, with approximately six awards expected, and applications will be peer-reviewed for merit. Interested applicants can reach out to NCI DCTD CDP PIRB NOFO at NCICDPNOFO@mail.nih.gov or by phone at 240-276-7782, with the application period anticipated to open in April 2026 and close in July 2026.

Through this limited competition Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications to support continuation of the two distinct biospecimen banking resources:The National Clinical Trials Network (NCTN) Biospecimen Banks (NCTN Biobanks) support the NCI-funded NCTN and the Community Oncology Research Program (NCORP), andThe Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) support the Experimental Therapeutics Clinical Trials Network (ETCTN) and NCI-supported other early phase and experimental clinical trials.The objective is to maintain these robust national resources for continuing the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. The goal of these resources is to ensure availability of biospecimens from participants in NCI-funded clinical trials focused on treatment, prevention, and cancer control studies to enable translational cancer research. NCTN Biobanks support the biobanking operations of the NCTN funded through the Cancer Therapy Evaluation Program (CTEP) and NCORP funded through the Division of Cancer Prevention (DCP). The clinical trials conducted through NCTN and NCORP enroll thousands of patients with adult and childhood cancers each year. NCTN Biobank operations aim to facilitate hypothesis-driven biomarker development and validation, secondary research studies, and broader scientific discovery. Biospecimens collected through harmonized protocols and long-term follow-up across large multi-site clinical trials provide valuable resources for studying disease mechanisms, therapeutic response, and clinical outcomes in different types of cancers.This NOFO will also support the continuation of the EET Biobank, a dedicated resource with a primary focus on meeting the biospecimen banking needs of the ETCTN and other early-phase and experimental clinical trials involving investigational new drugs (INDs). Biospecimens collected from the early phase clinical trials enable validated biomarker assay development, pharmacokinetic and pharmacodynamic studies, investigation of drug action and resistance mechanisms, improved patient stratification, and broader scientific discovery. Unlike the NCTN Biobank, the EET Biobank bridges basic science and clinical applications that enable acceleration of NCI&#8217;s IND development efforts for effective cancer treatments. This is a forecast for a limited competition Notice of Funding Opportunity (NOFO) that will invite application(s) from eligible organizations to apply. Application(s) will be peer-reviewed and only funded if meritorious.Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)

Buyer

Eligible Applicants

Funding Category

Funding Instrument

Opportunity Category

Cost Sharing or Matching Requirement

Original Source